On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
WednesdayFeb 26, 2020 1:38 pm

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Featured in ROTH Equity Research Report

Moleculin Biotech, Inc. (NASDAQ: MBRX) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Late last week, MBRX presented final Phase 1b results at the 4th Annual World Congress of Cutaneous Lymphomas, demonstrating median reduction of 56% in the CAILS score of index skin lesions in a per protocol analysis and a highly favorable safety profile with topical administration of p-STAT3 inhibitor WP1220. The results in these five patients is a final update from 4Q19's interim analysis of four patients, in which three of the four that completed dosing showed 70.8% CAILS…

Continue Reading

WednesdayFeb 26, 2020 1:29 pm

NetworkNewsBreaks – Sharps Compliance Corp. (NASDAQ: SMED) Featured in ROTH Equity Research Report

Sharps Compliance Corp. (NASDAQ: SMED) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We recently had SMED on the road for investor meetings. Route-based Collection now services 31 states increasing SMED’s ability to service multi-state customers creating larger contract opportunities. Unused Medication (MedSafe) deployments likely see similar deployment as calendar 2019 (1,500+units) leading to an installed base of over 6,000 units. Margins likely continue to expand as revenues leverage fixed cost leading to 45-50% incremental margins. We lift our target to $6.50.” To request access to the full report, visit http://nnw.fm/DXCr3…

Continue Reading

WednesdayFeb 26, 2020 1:19 pm

NetworkNewsBreaks – Lantronix, Inc. (NASDAQ: LTRX) Featured in ROTH Equity Research Report

Lantronix, Inc. (NASDAQ: LTRX) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “After a decade of stagnant sales, Lantronix has upgraded its C-suite and DNA under incoming CEO, Paul Pickle (ex-President and COO of Microsemi). Additionally, product expansion and two recent acquisitions have filled product gaps, expanded distribution, and added to scale and profitability. Overall, Lantronix has quickly transformed from a marginal IoT player, to be a more meaningful vendor in the Industrial IoT (IIoT) and emerging private network ecosystem. We initiate coverage with a Buy and $6PT.” To request access…

Continue Reading

WednesdayFeb 26, 2020 1:01 pm

NetworkNewsBreaks – Enphase Energy, Inc. (NASDAQ: ENPH) Featured in ROTH Equity Research Report

Enphase Energy, Inc. (NASDAQ: ENPH) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Heading into Q4 results, we had previewed potential for weakness in shares on potential coronavirus issues and channel inventory. It appears we may have misread the situation, and management has a path to likely sidestep the challenges assuming the situation in China remains stable and improves. All in, ENPH delivered an impressive Q4 and strong Q1 guide, and we continue to see upside to shares. Reiterate Buy and 2020 Top Pick, PT to $55 from $30.” To request…

Continue Reading

WednesdayFeb 26, 2020 12:52 pm

NetworkNewsBreaks – Shopify Inc. (NYSE: SHOP) Featured in ROTH Equity Research Report

Shopify Inc. (NYSE: SHOP) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Incremental Merchant solution strength (Shopify Pay and other tools adoption) resulted in 4Q outperformance and a ~230bps re-acceleration in topline growth. Growth rates overall (revenue/metrics) continue to trend lower with additional slowdowns implied in the modestly better FY20 revenue guidance (~1,000bps slowdown at the top end), with incremental growth investments suppressing profits. While we believe SHOP has numerous growth drivers at its disposal, high cost and longer lead times likely don’t drive sustainable growth acceleration (despite healthy fundamentals). Maintain…

Continue Reading

WednesdayFeb 26, 2020 12:43 pm

NetworkNewsBreaks – Applied Genetic Technologies Corporation (NASDAQ: AGTC) Featured in ROTH Equity Research Report

Applied Genetic Technologies Corporation (NASDAQ: AGTC) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “This morning, AGTC announced that the final two dose-cohorts of its Phase 1/2 XLRP study are now fully-enrolled. AGTC enrolled a total of nine patients into the higher and highest dose-cohorts, and plans to present interim data in 2H20, along with 12-month data from Groups 1-4. The updated data should provide insights on the appropriate time-point for analysis, as well as the influence of higher doses on endpoints of interest ahead of the initiation of a pivotal…

Continue Reading

WednesdayFeb 26, 2020 12:34 pm

NetworkNewsBreaks – Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) Featured in ROTH Equity Research Report

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “This morning, ALNA announced proposed changes to URIROX-2, including reduction of overall EH patients (200 vs. 400) and adding an interim analysis of 130 patients at six months treated expected 3Q21, with full readout for BLA filing in 1Q22. As discussed in our report below, we believe strong stat. sig. UOx reductions from URIROX-1 and KS rates reduce risk from decreasing the number patients studied. Importantly, we see streamlining as limiting any financial overhang (~1/3 the cost of…

Continue Reading

WednesdayFeb 26, 2020 12:22 pm

NetworkNewsBreaks – Evolus, Inc. (NASDAQ: EOLS) Featured in Mizuho Securities Research Report

Evolus, Inc. (NASDAQ: EOLS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Evolus reported full 4Q19 results today that were solid but largely expected following the company's pre-announcement on Jan 9. We maintain our BUY rating on EOLS shares as we expect the company to continue to execute on the commercialization of Jeuveau in a highly attractive facial toxin market. However, we appreciate that investors remain concerned about the ongoing legal issues between their partner Daewoong and competitor Medytox over Jeuveau’s development and that will remain an overhang for the stock,…

Continue Reading

WednesdayFeb 26, 2020 12:21 pm

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach

Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all…

Continue Reading

WednesdayFeb 26, 2020 11:43 am

NetworkNewsBreaks – Xencor, Inc. (NASDAQ: XNCR) Featured in Mizuho Securities Research Report

Xencor, Inc. (NASDAQ: XNCR) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “XNCR's 4Q19 EPS update was largely in line with our thesis as we see 2020 as a year of gaining visibility on the critical paths for wholly-owned T-cell engagers (TCEs), most notably plamotamab for B cell malignancies, which showed potential for advancement at ASH this past year. We see the next steps for plamotamab as locking down dose and schedule in 2020, and we expect incremental news from other pipeline candidates, which we see as valuation expansion opportunities. 4Q19…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217